Aqueous Shunts and Stents for Glaucoma Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

Aqueous Shunts and Stents for Glaucoma Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

Aqueous Shunts and Stents for Glaucoma Market Overview

The market for aqueous shunts and stents for glaucoma treatment is expected to experience steady growth, driven by the increasing prevalence of glaucoma globally and the rising demand for minimally invasive surgical options. With a growing focus on improving patient outcomes and reducing the risk of complications associated with traditional glaucoma surgeries, aqueous shunts and stents are becoming essential tools in the management of intraocular pressure (IOP). The market is particularly poised for growth due to advancements in technology, including the development of innovative shunt designs and drug-eluting stents that provide longer-term efficacy.

Market Size

The global market for aqueous shunts and stents for glaucoma is anticipated to grow at a compound annual growth rate (CAGR) ranging from 7% to 9% over the forecast period. The growth is driven by factors such as the aging population, increasing adoption of minimally invasive techniques, and advancements in glaucoma management technologies that enhance the efficacy and safety of aqueous shunts and stents.

Market Share & Trends Analysis

By Product Type

Aqueous shunts and stents for glaucoma are primarily divided into three product types: Trabecular Meshwork-Schlemm Canal Drainage, Subconjunctival Drainage, and Others. Each type is witnessing varying levels of adoption based on clinical needs and advancements in technology.

• Trabecular Meshwork-Schlemm Canal Drainage: This segment is expected to see the highest growth, with a CAGR of 7% to 9%, owing to the effectiveness of this approach in providing long-term IOP control and its widespread use in both primary and secondary glaucoma treatments. It remains the preferred choice for many patients requiring glaucoma drainage surgery.
• Subconjunctival Drainage: The subconjunctival drainage segment is expected to grow at a moderate rate, with a CAGR ranging from 6% to 8%. This approach is favored for patients with more complex forms of glaucoma or those who do not respond well to first-line treatments, contributing to its continued adoption in specialized ophthalmology centers.
• Others: The "Others" category includes emerging product types that are still in the development phase, such as drug-eluting stents and minimally invasive surgical devices. This segment is expected to grow rapidly with a CAGR of 8% to 10% as new technologies enter the market, providing novel treatment options for glaucoma management.

By Application

The applications of aqueous shunts and stents for glaucoma are primarily concentrated in hospitals and ophthalmology clinics. The growth of this market is linked to the increasing number of surgical procedures performed and the adoption of advanced surgical techniques for glaucoma management.

• Hospitals: Hospitals are expected to hold the largest share of the market, with a growth rate of 7% to 9% CAGR. As the primary settings for glaucoma surgeries, hospitals continue to see high demand for aqueous shunts and stents due to their role in managing IOP and reducing the risk of further damage to the optic nerve.
• Ophthalmology Clinics: Ophthalmology clinics are projected to experience a slightly lower growth rate, with a CAGR of 6% to 8%. Clinics are increasingly adopting aqueous shunts and stents as part of a more specialized approach to glaucoma care, focusing on providing personalized treatment options to patients.
• Others: Other application settings, such as outpatient surgical centers and specialized glaucoma clinics, are also expected to see moderate growth, with a CAGR of 5% to 7%. These facilities are becoming more common in regions with growing access to healthcare services.

By Key Players

The market for aqueous shunts and stents is highly competitive, with several key players dominating the landscape. These companies are focused on expanding their portfolios through innovation and improving patient outcomes with advanced technologies. Some of the key players in the market include:

• AbbVie: A global leader in ophthalmic treatments, AbbVie offers advanced glaucoma management solutions, including aqueous shunts and stents.
• Santen Pharmaceutical: Santen is known for its focus on developing treatments for glaucoma, with a range of aqueous shunts and stents aimed at improving patient quality of life.
• Johnson & Johnson: J&J offers a wide array of ophthalmic products, including shunts and stents designed to treat glaucoma with minimal invasiveness.
• Advanced Ophthalmic Innovations (AOI): AOI focuses on providing specialized glaucoma solutions, with innovative approaches in shunt and stent technology.
• New World Medical: Known for the development of the Ahmed Glaucoma Valve, New World Medical is a key player in the aqueous shunt market for glaucoma treatment.
• Nova Eye Medical: Nova Eye Medical is focused on developing and commercializing novel surgical technologies, including innovative aqueous stents for glaucoma patients.
• Glaukos Corp: Glaukos is a leading innovator in the glaucoma space, with its iStent system providing a minimally invasive option for reducing IOP in glaucoma patients.
• Alcon: Alcon offers a wide range of ophthalmic surgical devices, including aqueous shunts and stents designed for effective glaucoma treatment.
• iSTAR Medical: iSTAR Medical is focused on advancing glaucoma surgery with its proprietary miniaturized stent technologies.
• Henan Universe: A key player in the Chinese market, Henan Universe is increasing its presence with a variety of glaucoma drainage solutions.
• Ocular Therapeutix: Known for its drug-eluting glaucoma stents, Ocular Therapeutix is pioneering advanced solutions for glaucoma management.
• PolyActiva: PolyActiva is advancing the development of biodegradable aqueous shunts with drug-eluting properties, expected to improve patient outcomes in glaucoma treatment.
• Health Guard Biomed: Health Guard Biomed specializes in developing cutting-edge technologies for the treatment of glaucoma, including aqueous stents with enhanced performance.

By Region

The market for aqueous shunts and stents for glaucoma is expected to grow steadily across different regions, with North America and Europe leading the market. The Asia-Pacific region is expected to experience the highest growth due to increasing healthcare access and rising glaucoma awareness in emerging markets.

• North America: North America is projected to dominate the market with a CAGR of 7% to 9%, driven by the well-established healthcare infrastructure and high rates of glaucoma diagnosis and treatment.
• Europe: Europe is expected to experience steady growth, with a CAGR of 6% to 8%, due to strong healthcare systems and a high prevalence of glaucoma in the aging population.
• Asia-Pacific: The Asia-Pacific region is poised for the fastest growth, with a CAGR of 8% to 10%, driven by increasing access to healthcare, growing awareness of glaucoma, and the expansion of ophthalmic surgical centers.
• Latin America and Middle East & Africa: These regions are expected to grow at a moderate pace, with a CAGR of 5% to 7%, supported by improvements in healthcare infrastructure and rising medical tourism.

Segment Forecasts (2025-2030)

Growth in Key Segments

• Trabecular Meshwork-Schlemm Canal Drainage: This segment is expected to grow at a robust pace, with a CAGR of 7% to 9%, due to its effectiveness in managing IOP in patients with both primary and secondary glaucoma.
• Subconjunctival Drainage: Expected to grow at a moderate rate, with a CAGR of 6% to 8%, driven by its use in complex cases requiring alternative drainage techniques.
• Others: This segment, including innovative drug-eluting stents, is projected to see the highest growth, with a CAGR of 8% to 10%, as new technologies continue to emerge.